8,478 results match your criteria Gastrointestinal Stromal Tumors


[Diagnosis and surgical treatment of duodenal tumors].

Khirurgiia (Mosk) 2019 (1):5-13

A.V. Vishnevsky Institute of Surgery, Moscow, Russia.

Aim: To present the experience in diagnosis and surgical treatment of duodenal tumors.

Material And Methods: The study included 27 patients with different duodenal tumors: adenocarcinoma (AC, n=8), gastrointestinal stromal tumor (GIST, n=13), neuroendocrine tumor (NET, n=6). The examination included computed tomography (in 27 patients), magnetic resonance imaging (12), transcutaneous ultrasound (14), endosonography (16), esophagogastroduodenoscopy (16). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/hirurgia20190115DOI Listing
January 2019

Gastrointestinal stromal tumors: a comprehensive review.

J Gastrointest Oncol 2019 Feb;10(1):144-154

Department of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.

Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract associated with high rates of malignant transformation. Most GISTs present asymptomatically. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2018.08.20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351301PMC
February 2019

Extra-gastrointestinal stromal tumor with a large cyst.

J Surg Case Rep 2019 Feb 8;2019(2):rjy354. Epub 2019 Feb 8.

Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.

Gastrointestinal stromal tumors (GISTs) arising at sites other than the alimentary tract are rare, and they are called extra-GISTs (EGISTs). We report a case of a large EGIST forming a cyst, probably arising in the mesentery of the transverse colon. A 64-year-old Japanese man presented to a hospital with an abdominal tumor forming a large cyst. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjy354DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368142PMC
February 2019

Digital image analysis-based scoring system for endoscopic ultrasonography is useful in predicting gastrointestinal stromal tumors.

Gastric Cancer 2019 Feb 18. Epub 2019 Feb 18.

Department of Surgery, Pusan National University School of Medicine, Busan, South Korea.

Background: When gastric mesenchymal tumors (GMTs) measuring 2-5 cm in size are found, whether to undergo further treatment or not is controversial. Endoscopic ultrasonography (EUS) is useful for the evaluation of malignant potential of GMTs, but has limitations, such as subjective interpretation of EUS images. Therefore, we aimed to develop a scoring system based on the digital image analysis of EUS images to predict gastrointestinal stromal tumors (GISTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-019-00928-wDOI Listing
February 2019

[Two Cases of Resectable Intra-Abdominal Desmoid Tumor after Laparoscopic Gastrectomy for Gastric Cancer].

Gan To Kagaku Ryoho 2019 Jan;46(1):118-120

Dept. of Gastroenterological Surgery, Sendai Kousei Hospital.

Case 1: A 52-year-old man underwent laparoscopic total gastrectomy for gastric cancer. After 2 years, a follow-up computed tomography(CT)scan showed a large, solid 10 cm-sized mass in his left upper abdomen. Under the diagnosis of a suspected mesenchymal tumor, a tumor resection with a partial resection of the upper jejunum and transverse colon was performed. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.

J Clin Invest 2019 Feb 14. Epub 2019 Feb 14.

Gastrointestinal stromal tumor (GIST) is the most common human sarcoma, frequently characterized by an oncogenic mutation in the KIT or platelet-derived growth factor receptor alpha (PDGFRA) genes. We performed RNA sequencing of 75 human GIST tumors from 75 patients, comprising the largest cohort of GISTs sequenced to date, in order to discover differences in the immune infiltrates of KIT and PDGFRA-mutant GIST. Through bioinformatics, immunohistochemistry, and flow cytometry, we found that PDGFRA-mutant GISTs harbored more immune cells with increased cytolytic activity when compared to KIT-mutant GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI124108DOI Listing
February 2019

PRE-OPERATIVE GASTRIC GIST DOWNSIZING: THE IMPORTANCE OF NEOADJUVANT THERAPY.

Arq Bras Cir Dig 2019 Feb 7;32(1):e1427. Epub 2019 Feb 7.

Hospital das Clínicas, Universidade Federal de Minas Gerais, Alfa Institute of Gastroenterology, Belo Horizonte, MG, Brazil.

Introduction: Gastric gastrointestinal tumors (GIST) are a rare and usually asymptomatic neoplasm that can present as abdominal mass in more advanced scenarios. Since surgical resection is the main aspect of the treatment, locally advanced tumors require multivisceral resection and, therefore, higher postoperative morbidity and mortality.

Objective: To perform a review the literature on the topic, with emphasis on the neoadjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0102-672020180001e1427DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368167PMC
February 2019
1 Read

Gastrointestinal stromal tumor leading to acute abdomen and hypovolemic shock in a trauma patient.

Ulus Travma Acil Cerrahi Derg 2019 Jan;25(1):83-85

Department of General Surgery, İstanbul Medicine Hospital, İstanbul-Turkey.

Gastrointestinal stromal tumors (GISTs) are among the rare tumors of gastrointestinal (GI) tract. GISTs occur respectively in the stomach, small intestines, colon and rectum, omentum and mesentery, esophagus, retroperitoneal space, and abdominal cavity. However, they may occur anywhere along the GI tract. Read More

View Article

Download full-text PDF

Source
http://www.tjtes.org/eng/jvi.aspx?pdir=travma&plng=eng&a
Publisher Site
http://dx.doi.org/10.5505/tjtes.2018.35005DOI Listing
January 2019
4 Reads

Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors.

JAAD Case Rep 2019 Feb 30;5(2):170-172. Epub 2019 Jan 30.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.11.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357547PMC
February 2019

Submucosal 1-tunnel endoscopic resection for treating upper gastrointestinal multiple submucosal tumor originating from the muscularis propria layer: A report of 12 cases.

Medicine (Baltimore) 2019 Feb;98(6):e14484

Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

To explore the feasibility and efficacy of submucosal 1-tunnel endoscopic resection (1-tunnel STER) for the treatment of multiple upper gastrointestinal submucosal tumors (GI-SMTs) originating from the muscularis propria (MP) layer.A total of 12 patients with multiple upper GI-SMTs (no less than 2 SMTs) who underwent 1-tunnel STER from April 2013 to October 2017 were included. Clinical data on general characteristics, operation-related parameters, adverse events, and follow-up results were recorded and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014484DOI Listing
February 2019

A mucosal incision assisted biopsy vs. endoscopic ultrasound-guided fine-needle aspiration with a rapid on-site evaluation for gastric subepithelial lesions: A randomized crossover study.

Dig Endosc 2019 Feb 5. Epub 2019 Feb 5.

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Objectives: This study aimed to compare the diagnostic yield of mucosal incision-assisted biopsy (MIAB) and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with a rapid on-site evaluation (ROSE) for gastric subepithelial lesions (SELs) suspected of being gastrointestinal stromal tumors (GISTs) with an intraluminal growth pattern.

Methods: This was a prospective randomized crossover, multicenter study. The primary outcome was the diagnostic yield of EUS-FNA and MIAB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/den.13367DOI Listing
February 2019
1 Read

Gastrointestinal stromal tumors. A clinicopathological study.

Saudi Med J 2019 Feb;40(2):126-130

Department of Surgery, College of Medicine, King Fahad Hospital of the University, University of Imam Abdurahman Bin Faisal, Al Khobar, Kingdom of Saudi Arabia. E-mail.

Objectives: To evaluate the clinical presentations and immunohistochemical (IHC) properties of gastrointestinal stromal tumors (GISTs) and to compare them to internationally published data.

Methods: Thirty-six patients diagnosed with GISTs between January 1997 and December 2015 were retrospectively studied in 2 tertiary hospitals. Immunohistochemical staining was carried out prospectively when it has not been completed fully at the beginning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15537/smj.2019.2.23913DOI Listing
February 2019
1 Read
0.554 Impact Factor

Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.

BMC Cancer 2019 Feb 4;19(1):119. Epub 2019 Feb 4.

Cancer Research Institute, The Catholic University of Korea, Seoul, South Korea.

Background: The CD133 transmembrane protein is a well-recognized stem cell marker that has been used to isolate putative cancer stem cell populations from gastric cancers (GCs). However, the molecular features or biomarkers underlying CD133 are largely unknown in GCs.

Methods: We performed gene expression profiling of CD133+ and CD133- cells sorted by flow cytometry from three GC cell lines to identify the CD133 expression signatures of GC. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5332-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360664PMC
February 2019
2 Reads

Value of contrast-enhanced harmonic endoscopic ultrasonography inthedifferentiationof gastrointestinal stromal tumors: a meta-analysis.

J Dig Dis 2019 Feb 3. Epub 2019 Feb 3.

Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China.

Objective: Ensuring the diagnosis and determining the malignant potential of gastrointestinal stromal tumors (GISTs) as early as possible is important when making clinical therapeutic decisions. Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is a valuable method for this task. This study aimed to estimate the ability of CH-EUS to discriminate GISTs from benign submucosal lesions (SMLs) and predict their malignant potential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1751-2980.12710DOI Listing
February 2019
2 Reads

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors.

Pharmacogenomics J 2019 Feb 4. Epub 2019 Feb 4.

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Imatinib has a mild toxicity profile, although severe adverse events may develop. In this pharmacogenetic pathway analysis the need for dose reduction and cessation of therapy was tested for an association with single nucleotide polymorphisms (SNPs) in genes related to imatinib pharmacology. Retrospective data from 315 patients with a gastrointestinal stromal tumor who received imatinib 400 mg o. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41397-019-0079-zDOI Listing
February 2019

Preoperative tyrosine kinase inhibitors risks bowel anastomotic healing in patients with advanced primary and recurrent/metastatic gastrointestinal stromal tumors--- A rose has its thorns.

Eur J Surg Oncol 2019 02 17;45(2):153-159. Epub 2018 Oct 17.

Department of Surgery, Chang Gung Memorial Hospital at LinKou, Chang Gung University Medical College, Taoyuan, Taiwan. Electronic address:

Background: The combination of tyrosine kinase inhibitors (TKIs) and surgery has created a paradigm shift for advanced primary and metastatic gastrointestinal stromal tumors (GISTs). However, the associated surgical morbidity rate is reportedly high, which we hypothesized is attributable to the adverse effects of the previous use of TKIs on bowel anastomosis healing.

Methods: A total of 613 GIST patients with (n = 108) and without (n = 505) preoperative TKI treatment were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.09.029DOI Listing
February 2019

Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.

EBioMedicine 2019 Jan 29. Epub 2019 Jan 29.

University Medical Center Goettingen, Department of Gastroenterology and Gastrointestinal Oncology, Goettingen, Germany. Electronic address:

Background: Cytosolic 5'-nucleotidase 1A (NT5C1A) dephosphorylates non-cyclic nucleoside monophosphates to produce nucleosides and inorganic phosphates. Here, we investigate NT5C1A expression in pancreatic ductal adenocarcinoma (PDAC) and its impact on gemcitabine metabolism and therapeutic efficacy.

Methods: NT5C1A expression was determined by semiquantitative immunohistochemistry using tissue microarrays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.01.037DOI Listing
January 2019
10 Reads

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.

Am J Clin Dermatol 2019 Feb 1. Epub 2019 Feb 1.

Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA.

Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0414-1
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0414-1DOI Listing
February 2019
3 Reads

[TNM classification of gynecologic malignancies : What remains to be done beyond 2017?]

Pathologe 2019 Feb;40(1):73-79

Pathologisches Institut, Ludwig-Maximilians-Universität München, München, Deutschland.

For some gynecologic malignancies, there are disagreements between the most recent WHO and TNM classifications and the recommendations of the International Collaboration of Cancer Reporting. These discrepancies are addressed and discussed in this paper. The WHO definition for primary vaginal cancer does not match the TNM definition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00292-018-0559-yDOI Listing
February 2019
1 Read

Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.

Onco Targets Ther 2019 18;12:635-645. Epub 2019 Jan 18.

Department of Surgery, The University of Melbourne, The Royal Melbourne Hospital, Parkville, VIC 3050, Australia,

Human malignancies are often the result of overexpressed and constitutively active receptor and non-receptor tyrosine kinases, which ultimately lead to the mediation of key tumor-driven pathways. Several tyrosine kinases (ie, EGFR, FGFR, PDGFR, VEGFR), are aberrantly activated in most common tumors, including leukemia, glioblastoma, gastrointestinal stromal tumors, non-small-cell lung cancer, and head and neck cancers. Iclusig™ (ponatinib, previously known as AP24534) is an orally active multi-tyrosine kinase inhibitor and is currently approved by the US Food and Drug Administration for patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, specifically targeting the BCR-ABL gene mutation, T315I. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/ponatinib-a-novel-multi-tyrosine-k
Publisher Site
http://dx.doi.org/10.2147/OTT.S189391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343508PMC
January 2019
3 Reads

Surgical treatment of gastrointestinal stromal tumours combined with imatinib treatment: a retrospective cohort analysis.

Transl Gastroenterol Hepatol 2018 27;3:108. Epub 2018 Dec 27.

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.

Background: Targeted therapies changed the treatment concepts of gastrointestinal stromal tumours significantly. As only possibility to cure surgical resection is the cornerstone of therapy. Thus it is necessary to find out which patients will benefit most regarding modality (neo- or adjuvant) and duration of chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tgh.2018.12.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327167PMC
December 2018
1 Read

Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors.

Ann Gastroenterol Surg 2019 Jan 27;3(1):43-49. Epub 2018 Sep 27.

Department of Gastroenterological Surgery Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.

Gastrointestinal stromal tumors (GIST) are rare and mesenchymal in origin with a yearly incidence of 10-15 cases per million people. If it is technically resectable, surgical resection is the mainstay of therapy regardless of tumor location,. Although complete (R0) resection can be achieved in up to 85% of patients with primary disease, approximately 50% of patients experience recurrence or metastases within 5 years of primary resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ags3.12211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345649PMC
January 2019

Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.

Cancer Med 2019 Jan 28. Epub 2019 Jan 28.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

The long-term effects of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention on advanced gastrointestinal stromal tumor (GIST) were evaluated. All 379 patients had metastatic or recurrent GIST and started 400 mg/d imatinib at the Asan Medical Center in periods 1 and 2 [2001-2007 (33.2%) and 2008-2014 (66. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cam4.1994
Publisher Site
http://dx.doi.org/10.1002/cam4.1994DOI Listing
January 2019
6 Reads

[Gastrointestinal Stromal Tumor of the Small Intestine with Dissemination Successfully Treated with Surgical Resection and Adjuvant Chemotherapy with Sunitinib-A Case Report].

Gan To Kagaku Ryoho 2018 Dec;45(13):2438-2440

Dept. of Surgery, Yamato Takada Municipal Hospital.

We report the case of a 73-year-old woman with repeated recurrent small intestinal gastrointestinal stromal tumor(GIST) who was referred to our hospital for best supportive care. She underwent surgical resection 4 times and developed recurrent tumors that were resistant to imatinib. She complained of right lower abdominal pain caused by the recurrent tumor. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

[A Case of GIST with Extensive Peritoneal Dissemination Controlled over Long-Term by Low-Dose, Intermittent Administration of Imatinib after Weight Loss Surgery].

Gan To Kagaku Ryoho 2018 Dec;45(13):2348-2350

Division of Digestive Surgery, Dept. of Surgery, Kyoto Prefectural University of Medicine.

A 67-year-old man presented with abdominal pain and fever. Many abdominal tumors were detected by enhanced computed tomography(CT). The largest tumor, measuring 20 cm, had perforated the ileum and formed an abscess. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

[A Case of Rectal Gastrointestinal Stromal Tumor(GIST)with Long-Term Survival Treated with Multidisciplinary Therapy].

Gan To Kagaku Ryoho 2018 Dec;45(13):2288-2290

Dept. of Surgery, Kashiwara Municipal Hospital.

We report a case of gastrointestinal stromal tumor(GIST)with long-term survival treated by multidisciplinary therapy, including surgery and imatinib to prevent repeated recurrence. A 76-year-old woman visited our hospital with difficulty in defecation and bloody bowel discharge. She was diagnosed with rectal GIST and underwent transanal partial resection of the rectum. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Mol Cancer Ther 2019 Jan 24. Epub 2019 Jan 24.

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, orally available, highly selective inhibitor of HSP90. Patients with advanced solid tumors received TAS-116 orally once daily (QD, step 1) or every other day (QOD, step 2) in 21-day cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-0831DOI Listing
January 2019
1 Read

Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer.

PLoS One 2019 24;14(1):e0211108. Epub 2019 Jan 24.

Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

Although small bowel cancer (SBC) is extremely rare, its prognosis is poor, and molecular mechanism of the SBC development remains unclear. The aim of our study is to elucidate whether DNA methylation of the promoter region of the cancer-specific methylation gene, cysteine dioxygenase 1 (CDO1), contributes to the carcinogenic process in SBC. The study group comprised patients with 53 patients with SBC, 107 colorectal cancer (CRC), and other rare tumors of the small intestine such as 4 malignant lymphomas, 2 leiomyosarcomas, and 9 gastrointestinal stromal tumors. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211108PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345476PMC
January 2019
5 Reads

Identification of imatinib-resistant long non-coding RNAs in gastrointestinal stromal tumors.

Oncol Lett 2019 Feb 11;17(2):2283-2295. Epub 2018 Dec 11.

Department of Radiotherapy and Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China.

Long non-coding RNAs (lncRNAs) are an abundant RNA species that belong to the competing endogenous RNA network, which serves a critical role in the development, diagnosis and progression of diseases. Using chip technology, the current study analyzed the expression of lncRNAs in paired normal gastric tissues, primary gastrointestinal stromal tumor (GIST) tissues and GIST tissues resistant to imatinib mesylate. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to predict potential tumorigenesis and drug resistance mechanisms. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9821
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9821DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341907PMC
February 2019
3 Reads

Gastrointestinal Stromal Tumors: How to Increase the Preoperative Endoscopic Ultrasonography Diagnostic Rate.

Authors:
Chia-Sheng Chu

J Med Ultrasound 2018 Oct-Dec;26(4):177-180. Epub 2018 Dec 14.

Division of Gastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JMU.JMU_104_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314094PMC
December 2018

Dedifferentiated gastrointestinal stromal tumor: Recent advances.

Ann Diagn Pathol 2018 Dec 18. Epub 2018 Dec 18.

Department of Pathology and Genomic Medicine, Houston Methodist Hospital and Weill Medical College of Cornell University, Houston, TX 77030, USA. Electronic address:

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal lesions of the gastrointestinal tract. A small minority of GISTs exhibit morphologic and phenotypic changes and differentiate into an unusual phenotype through the process of dedifferentiation. Dedifferentiation can occur either de novo or after prolonged treatment with imatinib, a selective tyrosine kinase inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2018.12.005DOI Listing
December 2018
5 Reads

Malignant paraganglioma of the posterior mediastinum: A case report with genetic analysis.

Mol Clin Oncol 2019 Jan 8;10(1):10-16. Epub 2018 Nov 8.

Division of Gastroenterology, Department of Internal Medicine, Sapporo Shirakaba-dai Hospital, Sapporo, Hokkaido 062-0052, Japan.

Paraganglioma and pheochromocytoma are rare neuroendocrine neoplasms that originate from chromaffin cells. In many of these tumors, several mutations are reported to occur in the genes of germline and/or somatic cells. A case of paraganglioma in the posterior mediastinum with highly malignant potential is reported. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/mco.2018.1758
Publisher Site
http://dx.doi.org/10.3892/mco.2018.1758DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313888PMC
January 2019
7 Reads

Malignant peripheral nerve sheath tumor of the transverse colon with peritoneal metastasis: a case report.

J Med Case Rep 2019 Jan 18;13(1):15. Epub 2019 Jan 18.

Department of Pathology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.

Background: Malignant peripheral nerve sheath tumors are malignant tumors arising from a peripheral nerve or displaying nerve sheath differentiation. Gastrointestinal malignant peripheral nerve sheath tumors are rare and malignant peripheral nerve sheath tumor of the colon is even rarer. To date, only five cases have been reported as malignant peripheral nerve sheath tumor arising in the colon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1896-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337829PMC
January 2019

Pediatric plexiform fibromyxoma: A PRISMA-compliant systematic literature review.

Medicine (Baltimore) 2019 Jan;98(3):e14186

Department of Pathology, National Hospital Organization Beppu Medical Center, 1473 Oaza-Uchikamado, Beppu, Oita, Japan.

Background: Plexiform fibromyxoma (PF) is a rare gastric mesenchymal tumor, with approximately 80 cases reported to date. Gastrointestinal stromal tumor, the most common primary mesenchymal tumor of the stomach, shows different biological and clinical characteristics between adult and pediatric patients.

Objectives: This systematic literature review was conducted to elucidate the pathological and clinical features of pediatric PF compared to adult PF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014186DOI Listing
January 2019
1 Read

What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?

Medicine (Baltimore) 2019 Jan;98(3):e14177

Department of Gastric Surgery, Fujian Medical University Union Hospital.

In gastrointestinal stromal tumors (GISTs), rupture is a high-risk feature; however, "tumor rupture" is inconsistently defined, and its prognostic value remains controversial.Six hundred ninety-one patients undergoing surgery for primary nonmetastatic GISTs from 2003 to 2015 at our institution were enrolled. The strict definitions of "tumor rupture" according to the Kinki GIST Study Group (KGSG) were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014177DOI Listing
January 2019
1 Read

Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor: A case report.

Medicine (Baltimore) 2019 Jan;98(3):e14060

Department of Gastrointestinal Surgical Oncology, The Hubei Cancer Hospital, Huazhong University of Science and Technology, Wuhan, China.

Rationale: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is characterized by KIT mutations. Patientsresistant to 1st-line imatinib therapy are usually given sunitinib assecond-line treatment, which provides a median progression-free survival of 8 to 12 months. We report the 1st case of metastatic jejunum GIST with a KIT exon 11 deletion that showed complete response (CR) to sunitinib for more than 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014060DOI Listing
January 2019
1 Read

Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs.

Medicine (Baltimore) 2019 Jan;98(2):e14045

Institute of Digestive Surgery and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Tenascin-C (TNC), an extracellular matrix glycoprotein, has been implicated in progression of various types of cancer. However, few reports exist on TNC expression in gastrointestinal stromal tumors (GISTs). We here attempted to investigate the expression pattern and prognostic significance of TNC in gastric GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336641PMC
January 2019
2 Reads

Collision Tumor of Adenocarcinoma and Gastrointestinal Stromal Tumor in the Small Bowel.

Case Rep Gastroenterol 2018 Sep-Dec;12(3):715-721. Epub 2018 Nov 28.

Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University Hospital, Tokyo, Japan.

We report a very rare case of collision tumor composed of primary adenocarcinoma of the jejunum and gastrointestinal stromal tumor (GIST). The patient was a 63-year-old man who visited our hospital for epigastralgia and vomiting. Abdominal computed tomography revealed a mass in the upper jejunum, with gastric and duodenal dilatation. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495246
Publisher Site
http://dx.doi.org/10.1159/000495246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323411PMC
November 2018
11 Reads

Hepatoid Carcinoma of the Ovary: Clinical, Histopathologic, and Immunophenotypic Features.

Arch Pathol Lab Med 2019 Jan 10. Epub 2019 Jan 10.

From the University of Illinois at Chicago (Dr Acosta); the Chicago Medical School of Rosalind Franklin University of Medicine and Science, North Chicago, Illinois (Dr Pins); and the Advocate Lutheran General Hospital and the James R. & Helen D. Russell Institute for Research & Innovation, Park Ridge, Illinois (Dr Pins).

Hepatoid carcinoma of the ovary (HCO) is a rare malignant tumor of uncertain histogenesis that was first described by Ishikura and Scully in the late 1980s. Unlike hepatoid yolk sac tumor (HYST), one of its main differential diagnoses, HCO usually presents in perimenopausal and postmenopausal women without gonadal dysgenesis. Most cases show advanced local disease at initial presentation, with diffuse intraperitoneal dissemination. Read More

View Article

Download full-text PDF

Source
http://www.archivesofpathology.org/doi/10.5858/arpa.2017-048
Publisher Site
http://dx.doi.org/10.5858/arpa.2017-0485-RSDOI Listing
January 2019
5 Reads

Therapeutic Challenges in the Management of Bleeding Duodenal Gastrointestinal Stromal Tumor: a Case Report and Review of Literature.

J Gastrointest Cancer 2019 Mar;50(1):170-174

Department of Pathology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, 160012, India.

Introduction: Duodenum is an uncommon site for the gastrointestinal stromal tumors (GISTs). Though the principles of management are the same of that elsewhere in the gastrointestinal tract, the anatomical complexity poses challenges in deciding the most appropriate treatment. A bleeding GIST further compounds the difficulty in managing such patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-018-00197-3DOI Listing
March 2019
1 Read

A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.

Invest New Drugs 2019 Jan 9. Epub 2019 Jan 9.

Eisai Co. Ltd., Tokyo, Japan.

Background We conducted a first-in-Japanese, phase I study of ontuxizumab, a humanized, anti-endosialin monoclonal antibody, to confirm its tolerability, safety, and pharmacokinetics, and identify exploratory efficacy. Methods This was a multicenter, multiple-dose, open-label study in Japanese patients aged ≥20 years with solid tumors, including gastric cancer (GC) or advanced hepatocellular carcinoma (HCC), who had failed standard chemotherapy. The study comprised two parts: part 1 (dose-escalation; ontuxizumab 2-12 mg/kg weekly) and part 2 (cohort-expansion; 4 or 8 mg/kg weekly, or 12 mg/kg biweekly). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0713-7DOI Listing
January 2019
1 Read

Submucosal Tunnel Endoscopic Resection for Esophageal Submucosal Tumors: A Multicenter Study.

Gastroenterol Res Pract 2018 2;2018:2149564. Epub 2018 Dec 2.

Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background: Submucosal tumors (SMTs) are primarily benign tumors, but some may have a malignant potential. Endoscopic submucosal dissection that has been used for removing esophageal SMTs could cause perforation. Submucosal tunnel endoscopic resection (STER) is an improved and an effective technique for treating esophageal SMTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2149564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304882PMC
December 2018
2 Reads

The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm.

Eur Radiol 2019 Jan 7. Epub 2019 Jan 7.

Department of General Surgery, Nanfang Hospital, Guangdong Provincial Engineering Technology Research Center of Minimally Invasive Surgery, Southern Medical University, No.1838, North Guangzhou Avenue, Guangzhou, 510515, Guangdong Province, China.

Objective: This study aimed to investigate the endoscopic ultrasound (EUS) and computed tomography (CT) features of gastric gastrointestinal stromal tumors (GISTs) for assessing potential malignancy and prognosis.

Methods: Fifty consecutive patients with primary gastric GISTs larger than 2 cm were retrospectively enrolled in this study. The association of CT and EUS features with malignancy was analyzed using univariate and stepwise logistic regression method. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5945-6DOI Listing
January 2019
3 Reads

Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents.

Clin Epigenetics 2019 Jan 7;11(1). Epub 2019 Jan 7.

Department of Pathology, Università Cattolica del Sacro Cuore, Largo F.Vito 1, 00168, Rome, Italy.

Background: Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) constitute a small KIT/PDGFRA-WT GIST subgroup featuring DNA methylation which, although pervasive, appears nevertheless not randomly distributed. Although often indolent, these tumors are mostly chemorefractory in aggressive cases. Promoter methylation-induced O-methylguanine DNA methyltransferase (MGMT) inactivation improves the efficacy of alkylating agents in gliomas, colorectal cancer and diffuse large B cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-018-0594-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322231PMC
January 2019
2 Reads

The risk factors about prognosis of 142 GIST patients with recurrence or metastasis: A retrospective study of single centre in Northern China.

J BUON 2018 Nov-Dec;23(6):1855-1861

Department of General Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R.China.

Purpose: In this retrospective study, we investigated the clinicopathologic features, prognosis as well as the factors contributing to prognosis of patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs).

Methods: A total 142 GIST patients with confirmed metastasis or recurrence with complete clinicopathologic and prognostic data were enrolled as research group, and 278 GISTs patients without metastasis or recurrence as control group between June 2003 and June 2013.

Results: Significant differences between research group and control group were revealed, including gender, age, primary tumor sites, tumor diameter, mitosis rate, CD117 expression, risk level, treatment methods and surgical types (p<0. Read More

View Article

Download full-text PDF

Source
January 2019
7 Reads

Gastrointestinal stromal tumors and synchronous intra-abdominal malignancies: Review of the literature.

J BUON 2018 Nov-Dec;23(6):1573-1579

Department of General Surgery, University Hospital of Larissa, Mezourlo, Larissa, Thessaly, 41110, Greece.

Purpose: Gastrointestinal stromal tumors (GISTs) are the most frequent neoplasms of mesenchymal origin affecting the gastrointestinal tract. GISTs quite frequently co-exist with other primary tumors in up to 33% of the cases. Such occurrence has been mainly described in the literature in the form of case reports and rarely of case series which hasn't been sufficient to prove if there is any association between these two entities. Read More

View Article

Download full-text PDF

Source
January 2019
1 Read

Unexpected Intraoperative Findings, Situations, and Complications in Bariatric Surgery.

Obes Surg 2019 Jan 4. Epub 2019 Jan 4.

The Obesity Clinic at Hospital General Tláhuac, Avenida la Turba # 655, Col. Villa Centroamericana y del Caribe, Delegación Tláhuac, Zip 13250, México City, Mexico.

Background: Bariatric surgery is considered a safe therapy to treat obesity. Postoperative complications are well known; however, there is a lack of data describing intraoperative complications and/or unexpected findings, and if there is further impact on outcomes.

Methods: Retrospective study with patients operated between 2013 and 2016 at a single institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-018-03672-9DOI Listing
January 2019
1 Read
3.747 Impact Factor

Effects of CO pneumoperitoneum on proliferation, apoptosis, and migration of gastrointestinal stromal tumor cells.

Surg Endosc 2019 Jan 2. Epub 2019 Jan 2.

Department of General Surgery, Shanghai Tenth people's Hospital, Tongji University, No. 301 Middle Yanchang Road, Shanghai, 200072, People's Republic of China.

Background: The purpose of the study was to investigate the proliferation and migration capability of human gastrointestinal stromal tumor line GIST-T1 after exposure to different pressures and times of CO pneumoperitoneum.

Methods: We established simulated CO pneumoperitoneum environment in vitro and divided the human GIST cell GIST-T1 into open control group, 8 mmHg CO pneumoperitoneum treatment group and 15 mmHg CO pneumoperitoneum treatment group. Each group was divided into two subgroups respectively cultured for 1 h and 3 h. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00464-018-06633-6DOI Listing
January 2019
1 Read